课题基金 / 基金详情

Prenatal Methamphetamine Exposure and Child Development in New Zealand and USA

Prenatal Methamphetamine Exposure and Child Development in New Zealand and USA
新西兰和美国的产前甲基苯丙胺暴露与儿童发育
批准号:
7133799
负责人:
LINDA L LAGASSE
金额:
$36.74万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-09-05 至 2012-08-31

项目摘要

项目成果

LINDA L LAGASSE的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本申请是对PAS-03-023药物成瘾国际研究合作的回应。我们收到了一份管理补充材料,将新西兰的奥克兰添加到我们关于产前甲基苯丙胺(MA)暴露对儿童结局影响的多地点婴儿发育、环境和生活方式(IDEAL)纵向研究中。我们已经建立了一个社区研究网络(CRN),其中包括来自爱荷华州、俄克拉荷马州、加州和夏威夷的不同研究人群的四个临床研究合作伙伴(CRP),这些地区孕妇普遍使用MA,并且这项为期3年的纵向研究的数据收集工作已经在进行中。补充资金用于招募和对新西兰队列进行新生儿和1个月评估。本研究的目的是将新西兰队列的纵向随访延长至3年。正在新西兰招募受试者,预计将有240例受试者接受MA暴露和匹配比较。拟议研究的纵向方案包括1年、2年和3年的年度访视以及2.5年的家庭访视。儿童的测量包括唤醒调节、认知、社会关系、神经运动、神经内分泌功能、行为问题和医疗状况。心理社会风险因素的措施包括养育环境和照顾者的特点。我们将检验与产前MA暴露对儿童结局影响相关的假设,当控制包括其他药物使用在内的协变量时;与心理社会风险因素介导产前MA暴露对儿童结局影响相关的假设。将单独分析奥克兰队列,并与更大的IDEAL样本一起分析。随着新西兰奥克兰作为第五个CRP加入IDEAL研究,我们将:(1)增加IDEAL研究的样本量;(2)通过研究MA纯度变异性较小且使用频率高于其他IDEAL研究中心的一组,增加产前MA暴露对婴儿结局的可观察影响;(3)增加我们对文化育儿和家庭外安置问题的作用的理解,包括对MA暴露儿童结局的社会政策,以及(4)为我们理解产前MA暴露对儿童结局的影响做出国际贡献。这项拟议的研究将促进我们对这一新出现的问题的科学理解,并提高我们为这些儿童制定适当干预措施的能力。
英文摘要
DESCRIPTION (provided by applicant): This application is in response to PAS-03-023 International Research Collaboration on Drug Addiction. We had received an administrative supplement that added Auckland, New Zealand to our multisite Infant Development, Environment And Lifestyle (IDEAL) longitudinal study of the effects of prenatal methamphetamine (MA) exposure on child outcome. We have already established a Community Research Network (CRN) that includes four Clinical Research Partners (CRPs), from diverse study populations in Iowa, Oklahoma, California, and Hawaii where MA use by pregnant women is prevalent and where data collection for this 3-year longitudinal study is already underway. The supplement provided funds to recruit and conduct newborn and 1-month assessments of the New Zealand cohort. The purpose of this study is to extend the longitudinal follow up of the New Zealand cohort to 3 years. Recruitment in New Zealand is underway and 240 subjects with MA exposure and matched comparisons are anticipated. The longitudinal protocol of the proposed study includes annual visits at 1, 2, and 3 years and a home visit at 2.5 years. Measures of child include domains of arousal regulation, cognition, social relationships, neuromotor, neuroendocrine function, behavior problems and medical status. Measures of psychosocial risk factors include caregiving context and caregiver characteristics. We will test hypotheses related to the effects of prenatal MA exposure on child outcome when covariates including other drug use are controlled; hypotheses related to the role of psychosocial risk factors mediating effects of prenatal MA exposure on child outcome. The Auckland cohort will be analyzed separately and together with the larger IDEAL sample. With Auckland, New Zealand added to the IDEAL study as a fifth CRP, we will: (1) Increase the sample size of the IDEAL study; (2) Increase the observable effects of prenatal MA exposure on infant outcome by studying a group with less variability in the purity of MA and with a higher frequency of use than in other IDEAL sites; (3) Increase our understanding of the role of cultural childrearing and out-of-home placement issues, including social policy on the outcome of MA exposed children, and (4) Make an international contribution to our understanding of the effect of prenatal MA exposure on child outcome. The proposed study will advance our scientific understanding of this emerging problem and enhance our ability to develop appropriate interventions for these children.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Prenatal Methamphetamine Exposure and Child Development in New Zealand and USA
Prenatal Methamphetamine Exposure and Child Development in New Zealand and USA
Prenatal Methamphetamine Exposure and Child Development in New Zealand and USA
Prenatal Methamphetamine Exposure and Child Development in New Zealand and USA
海外基金